Samalin Investment Counsel, LLC Vertex Pharmaceuticals Inc Transaction History

Samalin Investment Counsel, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $111,606 - $138,961	-475 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $14,392 - $16,963	-65 Reduced 12.04%	475 $124 Million
Q4 2021 Feb 15, 2022	SELL	$177.01 - $223.45 $4,425 - $5,586	-25 Reduced 4.42%	540 $119 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $2,720 - $3,044	15 Added 2.73%	565 $102 Million
Q2 2021 Aug 12, 2021	BUY	$187.49 - $221.1 $103,119 - $121,605	550 New	550 $110,000
Q1 2021 May 11, 2021	SELL	$207.02 - $241.31 $488,360 - $569,250	-2,359 Closed	0 $0
Q4 2020 Oct 13, 2022	BUY	$207.01 - $276.09 $322,728 - $430,424	1,559 Added 194.88%	2,359 $558,000
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $322,728 - $430,424	1,559 Added 194.88%	2,359 $558 Million
Q3 2020 Oct 13, 2022	BUY	$255.65 - $303.1 $204,520 - $242,480	800 New	800 $218,000
Q3 2020 Nov 10, 2020	BUY	$255.65 - $303.1 $204,520 - $242,480	800 New	800 $217,000
Q1 2020 May 04, 2020	SELL	$199.77 - $247.81 $59,931 - $74,343	-300 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$166.71 - $223.91 $50,013 - $67,173	300 New	300 $65,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Samalin Investment Counsel, LLC, based on Form 13F filings with the SEC.

Stay updated on Samalin Investment Counsel, LLC with notifications on news.